MARKET

HRMY

HRMY

Harmony Biosciences Holdings, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

26.22
-0.15
-0.57%
Closed 16:00 07/29 EDT
OPEN
26.72
PREV CLOSE
26.37
HIGH
27.18
LOW
25.84
VOLUME
193.09K
TURNOVER
--
52 WEEK HIGH
52.74
52 WEEK LOW
25.09
MARKET CAP
1.65B
P/E (TTM)
-231.6254
1D
5D
1M
3M
1Y
5Y
John C. Jacobs, President And CEO Of Harmony Biosciences, Named An Ernst & Young (EY) Entrepreneur Of The Year 2021 Greater Philadelphia Award Winner
MEEETING, Pa., /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet med...
PR Newswire - PRF · 22h ago
Harmony Biosciences Announces Date Of Second Quarter 2021 Financial Results
Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, tod...
PR Newswire · 2d ago
Axsome (AXSM) Falls 10% After Losing Breakthrough Therapy Tag
Zacks.com · 07/15 14:05
Harmony Biosciences Initiates A Phase 2 Clinical Trial In Myotonic Dystrophy
Harmony Biosciences Holdings, Inc. ("Harmony") (NASDAQ:HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders
Benzinga · 06/29 12:08
/C O R R E C T I O N -- Harmony Biosciences/
Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today announced resu...
PR Newswire · 06/10 15:44
Harmony Bio reports clinical impact of Wakix in excessive daytime sleepiness at SLEEP 2021
Harmony Biosciences Holdings (HRMY) announces results of a new analysis evaluating number needed to treat ((NNT)) and effect sizes for treatment with WAKIX (pitolisant) that demonstrates the magnitude of its clinical
Seekingalpha · 06/10 12:25
Harmony Biosciences Presents New Analysis Of Clinical Impact For WAKIX® (pitolisant) At The SLEEP 2021 Annual Meeting
/PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, toda...
PR Newswire - PRF · 06/10 12:05
Harmony Biosciences Announces Applications for 2021 Patients At The Heart Grant Program Open June 9
/PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, toda...
PR Newswire - PRF · 06/09 12:05
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of HRMY. Analyze the recent business situations of Harmony Biosciences Holdings, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average HRMY stock price target is 52.00 with a high estimate of 59.00 and a low estimate of 43.00.
EPS
Institutional Holdings
Institutions: 55
Institutional Holdings: 27.47M
% Owned: 43.61%
Shares Outstanding: 62.98M
TypeInstitutionsShares
Increased
22
1.47M
New
8
289.12K
Decreased
15
1.48M
Sold Out
12
771.26K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.26%
Pharmaceuticals & Medical Research
-0.31%
Key Executives
Non-Executive Chairman
Jeffrey Aronin
President/Chief Executive Officer/Director
John Jacobs
Chief Financial Officer
Sandip Kapadia
Senior Vice President
Jeffrey Dierks
Other
Jeffrey Dayno
Other
Andrew Serafin
Independent Director
Antonio Gracias
Independent Director
R. Mark Graf
Independent Director
Eric Motley
Independent Director
Jack Nielsen
Independent Director
Aaron Royston
Independent Director
Juan Sabater
Independent Director
Gary Sender
Independent Director
Andreas Wicki
No Data
About HRMY
Harmony Biosciences Holdings, Inc. is a holding company. The Company through its subsidiary, Harmony Biosciences, LLC., operates as a pharmaceutical company, which is focused on therapies for patients suffering from central nervous system disorders living with medical needs. It provides treatment options for people living with rare and orphan diseases, with an emphasis on central nervous system disorders, patients living with narcolepsy. It enables to know narcolepsy and provides information and resources to individuals who live with, and healthcare professionals who treat patients with, this disorder. Narcolepsy is a chronic, debilitating neurologic disorder of sleep-wake state instability. The Company’s product, WAKIX (pitolisant), is a molecule with an action, designed to histamine signaling in the brain by binding to H3 receptors.

Webull offers kinds of Harmony Biosciences Holdings Inc stock information, including NASDAQ:HRMY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HRMY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HRMY stock methods without spending real money on the virtual paper trading platform.